China Precision Oncology Implementation Sessions: Clinical Trials, AI and Patient Access
A China-focused precision oncology implementation event examining how clinical trials and AI-enabled innovation can translate into trusted, timely and equitable patient access. The event will connect global evidence generation, local implementation, trial matching, diagnostics, patient navigation, real-world evidence and responsible AI governance.
Event details
Event type
Implementation Lab
Format
Two China-focused implementation sessions on precision oncology access. The first session focuses on global clinical trials and local patient benefit. The second focuses on trusted AI, patient access, trial matching, diagnostics and real-world evidence.
Audience
Chinese and international clinical leaders, hospital research networks, oncology experts, patient organisations, regulators, HTA and reimbursement stakeholders, diagnostics and pathology experts, AI and digital-health leaders, trial networks, industry partners and implementation experts.
Why this event matters
China is becoming a critical setting for precision oncology implementation. Its expanding clinical research capacity, hospital networks, regulatory modernisation, digital infrastructure and growing role in global and China-led trials create a major opportunity to connect innovation with patient benefit.
But trial success and digital innovation do not automatically become access. Patients may still be delayed by weak referral pathways, late biomarker testing, uneven diagnostic capacity, limited trial matching, fragmented data systems, reimbursement uncertainty and gaps between evidence generation and routine care.
This event focuses on two access-critical questions: how clinical trials can be designed and implemented as part of a wider access pathway, and how AI can help cancer systems move faster without weakening safety, accountability, equity or patient trust.
Strategic frame
The event is built around the shift from innovation participation to implementation value.
The first session, Global Clinical Trials, Local Access, examines how China and international partners can move from trial participation to trial-enabled access. It asks how clinical research can strengthen the pathway from patient identification and testing to evidence generation, regulatory confidence, reimbursement and routine care.
The second session, The AI Leapfrog Effect in Precision Oncology, examines how AI can help cancer systems overcome specific access barriers in diagnostics, trial matching, patient navigation and real-world evidence, while ensuring that speed does not come at the expense of safety, equity, accountability or trust.
Together, the two sessions position China not only as a site for clinical research and digital innovation, but as a potential implementation partner in building faster, safer and more reliable pathways from evidence to patient benefit.
Core question
How can China and international partners turn clinical trials and AI-enabled innovation into trusted, timely and equitable patient access?
Agenda snapshot
Session 1 | Global Clinical Trials, Local Access
From Global Evidence to Local Patient Benefit in China and Beyond
This 75-minute session will examine how China and international partners can move from trial participation to trial-enabled access. Discussion will focus on patient identification, biomarker testing, imaging, pathology, trial matching, regulatory confidence, HTA, reimbursement, real-world evidence and hospital research networks.
Session 2 | The AI Leapfrog Effect in Precision Oncology
From Digital Innovation to Trusted Patient Access
This 75-minute session will examine how AI can help cancer systems improve access through digital pathology, radiology, triage, biomarker pathway activation, clinical trial matching, patient navigation and real-world evidence, while protecting safety, equity, accountability and patient trust.
Tracks, labs or working groups
Global Clinical Trials and Local Access
This track examines how clinical trials can be planned as part of a wider access pathway, from patient identification and biomarker testing to regulatory assessment, reimbursement, clinical adoption and real-world follow-up. It focuses on how China and international partners can connect clinical research with local imp
Expected output:
Practical principles for trial-to-access alignment, including biomarker testing, imaging, digital pathology, trial matching, real-world evidence, regulatory confidence, HTA, reimbursement and hospital research networks.
Trusted AI and Patient Access in Precision Oncology
This track examines how AI can help cancer systems leapfrog specific access barriers in diagnostics, trial matching, patient navigation and real-world evidence. It focuses on realistic use cases, local validation, patient-centred governance, clinical accountability, reimbursement, equity safeguards and trust.
Expected output:
A patient-centred AI access framework, including priority use cases, safeguards for trustworthy deployment and China-international collaboration opportunities.
China-International Implementation Collaboration
This track connects both sessions by identifying where China and international partners can collaborate after the event. Potential areas include hospital research networks, registries, real-world evidence platforms, digital pathology validation, AI-enabled trial matching, data-to-decision systems and responsible implem
Expected output:
A short list of China-focused collaboration opportunities for post-event validation and follow-up.
People and contributors
Denis Horgan
Expected outputs
This activity is designed to produce practical outputs that can support follow-up after the meeting. Depending on the format, outputs may include a public statement, implementation brief, consensus note, pathway prototype, readiness map, roadmap or stakeholder summary.
China Precision Oncology Implementation Brief
Trial-to-Access Implementation Principles
Patient-Centred AI Access Framework
China-International Collaboration Opportunities
Join us at China Precision Oncology Sessions
12 November 2026 | 20:00 - 21:00
SCHR 1001, Schreiber Center, 16 E. Pearson St., Chicago
Interested in this event?
IPM Alliance welcomes engagement from policymakers, scientific experts, patient organisations, health-system leaders, industry partners and implementation actors.